1. A 31-year-old man with PNH (paroxysmal nocturnal hemoglobinuria) maintained on eculizumab presents to an emergency department with sudden onset of severe headache, fever of 39.8°C, neck stiffness, and a petechial rash that appeared over the past two hours. He states he received his meningococcal vaccines before starting eculizumab three years ago and takes prophylactic penicillin V daily. Blood cultures are drawn. Which of the following best describes the correct immediate management and explains the pharmacological basis for this patient's vulnerability?
A) Await blood culture results and lumbar puncture findings before initiating antibiotics, because eculizumab-treated patients are paradoxically protected against meningococcal disease by the high circulating C3b levels that accumulate when terminal complement is blocked, providing enhanced opsonophagocytic clearance of Neisseria meningitidis.
B) Administer a repeat meningococcal booster vaccine immediately and defer antibiotics for 48 hours to allow vaccine-induced bactericidal antibody titers to rise before exposing the organism to antibiotic selection pressure; eculizumab does not significantly increase meningococcal risk in vaccinated patients who maintain adequate anti-meningococcal IgG titers.
C) Administer empiric ceftriaxone immediately without waiting for culture results; eculizumab blocks MAC (membrane attack complex) formation, eliminating the terminal complement-mediated bactericidal defense that is the primary host mechanism for killing Neisseria meningitidis — vaccination and prophylactic antibiotics reduce but do not eliminate this risk, and suspected meningococcal disease in a complement-inhibited patient is a medical emergency requiring immediate treatment.
D) Discontinue eculizumab immediately to restore complement function before initiating antibiotics; the complement system will recover within 24 to 48 hours of drug discontinuation, providing sufficient terminal complement activity to assist antibiotic-mediated clearance of the organism before irreversible septic complications develop.
E) Administer IVIG at immunomodulatory dosing (1 to 2 g/kg) as the primary intervention; the pooled donor IgG will provide bactericidal anti-meningococcal antibodies from immune donors that directly opsonize the organism, compensating for the absent MAC-mediated lysis while eculizumab therapy continues uninterrupted.
ANSWER: C
Rationale:
Eculizumab blocks C5 cleavage and abolishes MAC (membrane attack complex) formation — the terminal complement pore that is the primary bactericidal mechanism against Neisseria meningitidis and other encapsulated Gram-negative organisms. Although meningococcal vaccination and prophylactic antibiotics substantially reduce the risk of breakthrough meningococcal disease, they do not eliminate it; breakthrough cases have been reported in vaccinated, antibiotic-prophylaxed patients on eculizumab. In a complement-inhibited patient, the clinical presentation of sudden fever, severe headache, neck stiffness, and petechial rash is a medical emergency — empiric broad-spectrum antibiotics covering meningococcus (ceftriaxone is first-line) must be given immediately, before culture results, before lumbar puncture if there is any delay risk, and without dose reduction or hesitation. Meningococcal sepsis can be fatal within hours in complement-deficient patients. This is an example of integrating pharmacological mechanism (MAC blockade) with the clinical consequence (fulminant susceptibility to Neisseria) to drive an urgent management decision.
Option A: Option A is incorrect because eculizumab does not provide paradoxical protection; while C3b opsonization is indeed intact (as eculizumab acts downstream of C3), this is insufficient to compensate for absent MAC-mediated bactericidal killing of Neisseria, which is uniquely dependent on terminal complement for clearance; awaiting cultures before antibiotics is dangerous.
Option B: Option B is incorrect because meningococcal vaccine does not generate rapid bactericidal antibody titers within 48 hours; the concept of vaccine-induced protection being adequate to defer antibiotics is pharmacologically unsound; empiric treatment must not be delayed.
Option D: Option D is incorrect because eculizumab has a half-life of approximately 11 days; complement function does not recover within 24 to 48 hours of discontinuation; and delaying antibiotics to await complement recovery would be fatal in suspected meningococcal disease.
Option E: Option E is incorrect because IVIG does not specifically contain high-titer bactericidal anti-meningococcal antibodies and is not an appropriate treatment for suspected bacterial meningitis or meningococcemia; empiric ceftriaxone, not IVIG, is the standard of care.
2. A 40-year-old woman with PNH on eculizumab has well-controlled intravascular hemolysis — her LDH (lactate dehydrogenase) is consistently normal and she has had no hemoglobinuria for two years. However, her hemoglobin has plateaued at 9.0 g/dL despite dose-compliant therapy, and laboratory testing shows an elevated indirect bilirubin and reticulocyte count with a normal LDH. Her hematologist concludes that a specific complement-mediated process not addressed by eculizumab is responsible. Switching to ravulizumab is proposed by a consultant. Which of the following best evaluates this proposal and identifies the more appropriate intervention?
A) Switching to ravulizumab is not appropriate because ravulizumab has the same mechanism as eculizumab — C5 blockade — and would not address the residual extravascular hemolysis driven by C3b opsonization of PNH erythrocytes, which occurs upstream of C5; agents that inhibit C3 (pegcetacoplan) or Factor B upstream of C3b amplification (iptacopan) are the appropriate options for this patient.
B) Switching to ravulizumab is appropriate because its longer half-life eliminates the two-week trough periods of eculizumab during which C5 cleavage resumes, allowing C3b to deposit on PNH erythrocytes; continuous C5 blockade with ravulizumab will prevent this trough-period C3b deposition and resolve the extravascular hemolysis.
C) The laboratory pattern described — elevated indirect bilirubin and reticulocyte count with normal LDH — is consistent with intravascular hemolysis that has been partially suppressed by eculizumab but not eliminated; increasing the eculizumab dose to achieve complete C5 blockade is the appropriate intervention before considering alternative agents.
D) Switching to ravulizumab is appropriate because ravulizumab, unlike eculizumab, also inhibits C3 convertase activity through an allosteric mechanism acquired through its Fc engineering; this dual C5 and C3 blockade prevents both intravascular and extravascular hemolysis in PNH patients with residual anemia on eculizumab.
E) The normal LDH with elevated indirect bilirubin and reticulocytosis indicates hepatic involvement — specifically eculizumab-induced cholestasis from complement activation in the liver sinusoids; switching to an alternative complement inhibitor class such as avacopan, which blocks C5aR1, will reduce hepatic C5a-driven inflammation and normalize bilirubin.
ANSWER: A
Rationale:
The laboratory pattern is the key to this integration question. Normal LDH with elevated indirect bilirubin and high reticulocyte count in a PNH patient on anti-C5 therapy is the characteristic signature of extravascular hemolysis — not intravascular hemolysis, which produces elevated LDH, hemoglobinuria, and low haptoglobin. The distinction matters pharmacologically: intravascular hemolysis (MAC-mediated erythrocyte lysis in circulation) is well controlled by eculizumab; extravascular hemolysis (phagocytic destruction of C3b-opsonized erythrocytes in the liver and spleen) is not. Eculizumab blocks C5 cleavage but leaves C3 activation entirely intact — C3b continues to deposit on GPI-deficient PNH erythrocytes, opsonizing them for Kupffer cell and splenic macrophage phagocytosis. Ravulizumab shares the identical mechanism (C5 blockade) and would produce the same result; switching to it addresses dosing convenience but not extravascular hemolysis. Pegcetacoplan (C3 inhibitor, subcutaneous twice weekly) or iptacopan (oral Factor B inhibitor, monotherapy) both act upstream of C3b generation and would prevent C3b opsonization, addressing extravascular hemolysis.
Option B: Option B is incorrect because eculizumab's every-two-week dosing does not produce clinically significant trough periods of C5 activation that allow C3b deposition; C3b deposition occurs because anti-C5 therapy does not affect C3 at all — it is not a trough-period phenomenon.
Option C: Option C is incorrect because the laboratory pattern described (normal LDH, elevated indirect bilirubin, high reticulocytes) specifically indicates extravascular rather than intravascular hemolysis; increasing eculizumab dose would not address extravascular hemolysis since the mechanism (C3b opsonization) is upstream of C5.
Option D: Option D is incorrect because ravulizumab's Fc engineering increases FcRn affinity to extend half-life — it confers no C3 convertase inhibitory activity whatsoever; ravulizumab is a pure C5 inhibitor identical in mechanism to eculizumab.
Option E: Option E is incorrect because eculizumab-induced cholestasis is not a recognized mechanism; the hepatic bilirubin elevation in this scenario is indirect (unconjugated), consistent with hemolysis rather than cholestasis; avacopan is approved for ANCA vasculitis, not for PNH extravascular hemolysis.
3. A 22-year-old man who was EBV (Epstein-Barr virus)-seronegative at the time of kidney transplantation has been maintained on belatacept-based immunosuppression. Eight months post-transplant, he develops fever, cervical lymphadenopathy, and elevated EBV viral load on quantitative PCR. Biopsy of an enlarged cervical lymph node shows a polymorphic lymphoproliferative infiltrate. Which of the following best explains the mechanism linking belatacept to this complication, and what is the complication?
A) Belatacept causes secondary hypogammaglobulinemia by depleting mature B cells through Fc-mediated ADCC (antibody-dependent cellular cytotoxicity); in an EBV-seronegative patient acquiring primary EBV infection without adequate anti-EBV IgG, the virus spreads unchecked, causing EBV-associated lymphoproliferative disease driven by absent humoral immunity.
B) Belatacept activates the PD-1 (programmed cell death protein 1) co-inhibitory pathway as an off-target effect of CD80/CD86 blockade; PD-1 upregulation on EBV-specific CD8+ T cells causes exhaustion of the CTL (cytotoxic T-lymphocyte) response to primary EBV infection, allowing EBV-infected B cells to proliferate without immune control.
C) Belatacept's Fc region activates complement on EBV-infected B cells through the classical pathway, causing selective lysis of EBV-specific memory B cells that would otherwise provide long-term immunity; the resulting absence of EBV memory B cells prevents an effective recall response, allowing primary EBV infection to progress to lymphoproliferative disease.
D) This is post-transplant lymphoproliferative disorder (PTLD); belatacept's blockade of CD80/CD86-CD28 T-cell co-stimulation impairs the generation and maintenance of EBV-specific cytotoxic T lymphocytes (CTLs), which normally eliminate EBV-infected B cells; in an EBV-seronegative recipient acquiring primary infection, the absence of CTL surveillance allows unchecked EBV-driven B-cell proliferation, a risk sufficient to constitute an FDA contraindication to belatacept in this population.
E) This is EBV-associated hemophagocytic lymphohistiocytosis (HLH); belatacept suppresses NK cell activity by blocking the CD28-mediated co-stimulation required for NK cell priming, impairing perforin-granzyme-mediated killing of EBV-infected cells and triggering the cytokine storm characteristic of HLH in the setting of primary EBV infection.
ANSWER: D
Rationale:
This case illustrates the clinical consequence of the FDA contraindication to belatacept in EBV-seronegative transplant recipients. Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of B-cell lymphoproliferative conditions — ranging from polymorphic lymphoid hyperplasia to aggressive monoclonal lymphoma — driven by EBV-infected B cells proliferating without adequate immune control. In immunocompetent individuals, EBV-specific CD8+ cytotoxic T lymphocytes (CTLs) continuously survey and eliminate EBV-latently-infected B cells, maintaining viral latency and preventing lymphoproliferation. CTL priming and effector differentiation require the CD28 co-stimulatory signal that belatacept blocks by occupying CD80 and CD86 on antigen-presenting cells. In an EBV-seronegative recipient who acquires primary EBV infection post-transplant, no pre-existing EBV-specific CTL memory exists; generating de novo CTL responses requires robust co-stimulation that belatacept pharmacologically eliminates, leaving the patient unable to control EBV-infected B-cell proliferation. The biopsy showing a polymorphic lymphoproliferative infiltrate with elevated EBV PCR is the characteristic early PTLD presentation. This contraindication is listed in the belatacept FDA label and is one of its most important safety distinctions from calcineurin inhibitor-based regimens.
Option A: Option A is incorrect because belatacept does not deplete B cells — it is a T-cell co-stimulation blocker; B-cell depletion through Fc-mediated ADCC is the mechanism of anti-CD20 agents such as rituximab.
Option B: Option B is incorrect because belatacept does not directly activate the PD-1 pathway as an off-target mechanism; the CTL impairment is through CD28 co-stimulation blockade, not PD-1 upregulation; these are pharmacologically distinct checkpoints.
Option C: Option C is incorrect because belatacept's Fc region does not specifically lyse EBV-specific memory B cells; the drug blocks T-cell co-stimulation at the APC surface and has no selective cytotoxic activity against any B-cell subset.
Option E: Option E is incorrect because belatacept does not impair NK cell function through CD28 blockade — NK cells do not rely on CD28 co-stimulation for activation; and the clinical presentation described is PTLD (lymphoproliferation), not HLH (cytopenias, hyperferritinemia, hemophagocytosis).
4. A 67-year-old woman with rheumatoid arthritis maintained on tocilizumab and low-dose prednisone presents with three days of productive cough, pleuritic chest pain, and fever of 38.7°C. Her CRP is 6 mg/L (laboratory reference range <10 mg/L, reported as normal for this assay), her WBC (white blood cell count) is 14,200/mcL with 88% neutrophils, and her procalcitonin (PCT) is 2.8 ng/mL (elevated; reference <0.25 ng/mL). Chest radiograph shows a right lower lobe consolidation. Which of the following best integrates the pharmacological mechanism of tocilizumab with the interpretation of this biomarker pattern?
A) The CRP is unreliable because tocilizumab induces non-specific protease secretion from macrophages that degrades CRP in plasma; PCT should be interpreted cautiously because it is an acute-phase reactant also suppressed by IL-6R blockade, making it less reliable than blood cultures alone in this population.
B) Tocilizumab blocks IL-6 receptor signaling, which is the primary driver of hepatic CRP synthesis; the apparently normal CRP does not reflect the true inflammatory state and cannot be used to exclude bacterial infection; the elevated PCT, which is produced through IL-6-independent pathways stimulated by bacterial endotoxin and TNF, correctly identifies this as a bacterial infection requiring empiric antibiotic therapy.
C) The normal CRP in this tocilizumab-treated patient confirms that RA disease activity is quiescent and that the fever and consolidation represent a non-bacterial process such as organizing pneumonia or drug-induced pneumonitis; PCT should be repeated in 48 hours to establish a trend before committing to antibiotics.
D) Tocilizumab selectively suppresses CRP production only in the context of RA-driven inflammation; infection-driven CRP synthesis through toll-like receptor (TLR) pathways is IL-6-independent and therefore not suppressed; the normal CRP in this patient indicates a non-bacterial, non-inflammatory cause for the consolidation.
E) Both CRP and PCT are suppressed by tocilizumab because the drug blocks the entire hepatic acute-phase response; the leukocytosis with left shift is the only reliable inflammatory marker in this population and should be used as the primary guide for antibiotic initiation decisions in tocilizumab-treated patients.
ANSWER: B
Rationale:
This question requires integrating two pharmacological concepts: (1) the mechanism by which tocilizumab suppresses CRP, and (2) why procalcitonin escapes this suppression and remains a reliable infection biomarker. IL-6 is the principal cytokine driving hepatic CRP synthesis through JAK1-STAT3 signaling; tocilizumab blocks the IL-6 receptor (both soluble and membrane-bound forms), eliminating this signal regardless of whether IL-6 is elevated due to RA disease activity or due to infection. The result is constitutive pharmacological suppression of CRP that persists even during active bacterial infection — this patient's normal CRP is pharmacologically induced and entirely uninformative about infection status. Procalcitonin (PCT) is produced primarily by parenchymal cells (thyroid C-cells and non-thyroidal tissues) in response to bacterial endotoxin and to IL-1beta and TNF signaling — pathways upstream of or independent of IL-6; PCT production is not suppressed by IL-6R blockade and rises normally during bacterial infection. The elevated PCT of 2.8 ng/mL in this patient with fever, neutrophilia, and right lower lobe consolidation constitutes strong evidence for bacterial pneumonia requiring empiric antibiotics.
Option A: Option A is incorrect because tocilizumab does not cause macrophage protease secretion that degrades CRP; the suppression is at the level of hepatic CRP synthesis, not catabolism; and PCT is not suppressed by IL-6R blockade — it is the preferred biomarker precisely because it is IL-6-independent.
Option C: Option C is incorrect because the normal CRP in a tocilizumab-treated patient cannot be used to infer quiescent inflammation or exclude bacterial infection; the classic error being avoided here is treating a pharmacologically suppressed CRP as a true negative result.
Option D: Option D is incorrect because tocilizumab blocks IL-6 receptor signaling broadly — including infection-driven IL-6 released in response to TLR activation; the idea that infection-driven CRP synthesis escapes IL-6R blockade through a TLR pathway is pharmacologically incorrect.
Option E: Option E is incorrect because PCT is not suppressed by tocilizumab; the statement that both CRP and PCT are suppressed by IL-6R blockade is the critical misconception that this question is designed to correct.
5. An immunologist is teaching two cases to a group of residents. In Case 1, a patient with ITP (immune thrombocytopenic purpura) with a platelet count of 6,000/mcL receives high-dose IVIG and her platelet count rises to 95,000/mcL within 72 hours. In Case 2, a patient with GBS (Guillain-Barré syndrome) — an acute inflammatory demyelinating polyneuropathy — receives the same IVIG dose and begins to show measurable neurological improvement after 10 to 14 days. The immunologist asks the residents to explain the mechanistic basis for the dramatically different time courses of response in these two patients. Which of the following best accounts for this difference?
A) The difference in response time reflects the half-life of the target antibodies in each disease: anti-platelet IgG antibodies have a half-life of 12 to 24 hours and are rapidly cleared by FcRn-accelerated catabolism, while anti-ganglioside IgG antibodies in GBS have a half-life of 10 to 14 days, explaining the delayed response regardless of the IVIG mechanism engaged.
B) IVIG works in ITP by activating complement-dependent lysis of anti-platelet antibody-secreting plasma cells within 48 hours, rapidly reducing antibody production; in GBS, no plasma cells are involved — the damage is T-cell mediated — and IVIG must modulate the T-cell inflammatory response through Treg expansion, a process requiring 2 to 4 weeks.
C) The rapid platelet response in ITP reflects high splenic macrophage density that is quickly saturated by IVIG Fc-gamma receptor blockade; the slower response in GBS reflects lower peripheral nerve macrophage density, requiring more time for IVIG to achieve equivalent Fc-gamma receptor saturation at the site of nerve injury.
D) IVIG engages the same mechanism in both diseases — FcRn saturation and accelerated autoantibody catabolism — but anti-platelet antibodies are IgM class with a shorter half-life than the IgG anti-ganglioside antibodies in GBS; the pharmacokinetic difference between IgM and IgG catabolism accounts entirely for the different time courses.
E) The rapid platelet response in ITP primarily reflects Fc-gamma receptor blockade on splenic macrophages — a near-immediate physical blockade that prevents ongoing platelet phagocytosis within hours of achieving adequate IgG concentrations; the slower neurological improvement in GBS primarily reflects FcRn-mediated accelerated catabolism of pathogenic anti-ganglioside antibodies and reduction of complement-mediated nerve damage, processes that require days to weeks to manifest as clinical improvement even when the mechanism is engaged rapidly.
ANSWER: E
Rationale:
This question integrates IVIG's multiple mechanisms with their distinct time scales. In ITP, the dominant acute mechanism is Fc-gamma receptor (FcgammaRII/FcgammaRIII) blockade on splenic macrophages: the high bolus of IgG Fc regions physically saturates macrophage Fc receptors within hours, preventing them from recognizing and phagocytosing anti-platelet-antibody-opsonized platelets. Since platelets are not being destroyed while Fc receptors remain occupied, the platelet count rises rapidly — typically within 24 to 72 hours — as circulating platelets accumulate. In GBS, the target is the myelinated peripheral nerve; pathogenic anti-ganglioside antibodies (anti-GM1, anti-GQ1b, and others) mediate complement activation and axonal membrane damage. IVIG ameliorates GBS through FcRn-mediated accelerated catabolism of pathogenic IgG (reducing anti-ganglioside antibody levels over 10 to 14 days), anti-idiotypic neutralization of anti-ganglioside antibodies, and complement modulation — mechanisms that require time to reduce existing nerve damage and allow remyelination, which itself is a weeks-to-months process. The clinical improvement time course therefore reflects both the time for pathogenic antibody levels to fall and the biological time required for nerve repair to begin.
Option A: Option A is incorrect because anti-platelet IgG has a normal IgG half-life of approximately 21 days — the rapid ITP response is not due to rapid antibody catabolism; it is due to immediate Fc receptor blockade preventing platelet destruction.
Option B: Option B is incorrect because IVIG does not lyse plasma cells by complement-dependent cytotoxicity in ITP; and GBS is primarily antibody-mediated (anti-ganglioside IgG), not T-cell mediated — Treg expansion is not the principal IVIG mechanism in GBS.
Option C: Option C is incorrect because macrophage density differences do not account for the time course difference; Fc-gamma receptor blockade occurs systemically, not locally at the nerve; the mechanism of IVIG in GBS is not primarily Fc-gamma receptor blockade.
Option D: Option D is incorrect because anti-platelet antibodies in ITP are IgG (not IgM); FcRn-mediated catabolism does not distinguish IgM from IgG — IgM has a shorter half-life naturally but this is not the mechanism of the rapid ITP response.
6. A 59-year-old woman with seropositive rheumatoid arthritis maintained on abatacept and methotrexate is newly diagnosed with stage IIIA non-small cell lung cancer. Her oncologist proposes adding ipilimumab — a monoclonal antibody that blocks CTLA-4 — as part of a cancer immunotherapy regimen. Her rheumatologist raises a concern about a fundamental pharmacological conflict. Which of the following best explains the nature of this conflict and predicts the likely clinical consequence?
A) Abatacept and ipilimumab both bind CD80 and CD86 on antigen-presenting cells and will compete for the same binding sites; the combined use will produce neither co-stimulation blockade nor checkpoint inhibition, leaving the patient immunologically unmodulated — neither RA nor cancer will respond to the combination.
B) Ipilimumab is a monoclonal antibody that activates complement through its IgG1 Fc region on CTLA-4-expressing T cells, causing depletion of the regulatory T cells that abatacept depends on for its immunosuppressive effect; combining them will cause a rapid loss of abatacept efficacy and RA flare within weeks of ipilimumab initiation.
C) Abatacept delivers an agonist CTLA-4 signal by presenting CTLA-4 to CD80/CD86 on APCs (antigen-presenting cells), reinforcing T-cell inhibition — the mechanism that controls RA; ipilimumab blocks CTLA-4 to release T-cell inhibition for anti-tumor immunity — the pharmacologically opposite effect; combining them creates direct mechanistic opposition at the same checkpoint, likely reducing both agents' efficacy and potentially triggering immune-related inflammatory adverse events as the CTLA-4 brake is released.
D) Abatacept and ipilimumab are synergistic because abatacept suppresses CTLA-4 in the RA synovium while ipilimumab activates CTLA-4 in the tumor microenvironment; the two drugs act in different tissue compartments and their combination achieves simultaneous disease control in both the joint and the tumor without pharmacological conflict.
E) The conflict is pharmacokinetic rather than mechanistic: ipilimumab is a full IgG1 antibody metabolized by FcRn recycling, and abatacept's IgG1 Fc region competitively saturates FcRn, accelerating ipilimumab catabolism and reducing its plasma half-life by approximately 60%; the oncological efficacy of ipilimumab is therefore substantially impaired when co-administered with abatacept.
ANSWER: C
Rationale:
This question requires integrating the mechanisms of abatacept and ipilimumab at the CTLA-4 checkpoint and predicting the clinical consequence of pharmacological opposition. Abatacept is a CTLA-4-Ig fusion protein that presents the CTLA-4 extracellular domain to CD80/CD86 on APCs, competing with CD28 and delivering an inhibitory signal to T cells — this is how it suppresses autoreactive T-cell-driven inflammation in RA. CTLA-4 engagement normally functions as an inhibitory checkpoint; abatacept reinforces this brake. Ipilimumab is an anti-CTLA-4 monoclonal antibody that blocks CTLA-4 itself, preventing it from engaging CD80/CD86 — this releases the inhibitory brake on T cells, allowing anti-tumor T-cell responses to amplify. These two mechanisms are directly opposed at the same molecular checkpoint: abatacept activates the CTLA-4 brake; ipilimumab blocks it. Combining them is expected to reduce the efficacy of both — abatacept cannot deliver the CTLA-4 inhibitory signal while ipilimumab blocks CTLA-4 binding to CD80/CD86 — and releasing CTLA-4 inhibition in a patient already on T-cell immunosuppression may trigger immune-related adverse events (irAEs) such as inflammatory arthritis, colitis, thyroiditis, or pneumonitis as autoreactive T cells become activated. Clinically, this combination is generally contraindicated — patients cannot simultaneously receive a checkpoint activator for autoimmune disease and a checkpoint inhibitor for cancer without fundamental pharmacological conflict.
Option A: Option A is incorrect because the two drugs bind different molecules — abatacept binds CD80/CD86 at the APC, while ipilimumab binds CTLA-4 on the T cell; they do not compete for the same binding sites, and their combination produces mechanistic opposition rather than null effect.
Option B: Option B is incorrect because ipilimumab does not deplete regulatory T cells through complement activation; its mechanism is CTLA-4 blockade on effector T cells; Treg depletion is a recognized secondary effect but through Fc-gamma receptor-mediated ADCP in the tumor microenvironment, not complement-mediated lysis.
Option D: Option D is incorrect because there is no organ-specific compartmentalization of CTLA-4 checkpoint signaling that would allow simultaneous activation in one tissue and inhibition in another — the checkpoint operates systemically on circulating T cells.
Option E: Option E is incorrect because competitive FcRn saturation between two IgG molecules is not a clinically meaningful pharmacokinetic interaction; FcRn has sufficient capacity for both antibodies at therapeutic concentrations, and the interaction is mechanistic, not pharmacokinetic.
7. A 71-year-old woman with relapsed multiple myeloma on daratumumab is admitted after a fall with a traumatic splenic laceration requiring emergent surgery. Her pre-operative hemoglobin is 6.8 g/dL and the surgical team requests four units of packed red blood cells urgently. The blood bank calls the surgical attending to report that compatibility testing is showing a pan-reactive positive result on all donor units and that standard crossmatch interpretation is impossible. Which of the following best explains this result, identifies its cause, and describes the correct blood bank response?
A) Daratumumab has induced warm autoimmune hemolytic anemia by stimulating autoreactive B-cell clones that produce anti-erythrocyte antibodies coating the patient's red cells; the pan-reactive crossmatch reflects high-titer autoantibodies that mask alloantibodies; the correct response is plasmapheresis to remove autoantibodies before transfusion.
B) Daratumumab activates complement on the patient's erythrocytes through its IgG1 Fc region, coating them with C3b fragments that are detected by the anti-complement component of the DAT (direct antiglobulin test) reagent; the correct response is to use complement-inactivated donor serum for compatibility testing and standard crossmatch can proceed normally.
C) The pan-reactive positive result reflects HLA (human leukocyte antigen) antibody formation from prior transfusions, which is exacerbated by daratumumab-mediated B-cell hyperactivation; blood bank must use HLA-matched red cells and cannot use unmatched units regardless of the emergency, as incompatible transfusion risk outweighs hemorrhage risk in this setting.
D) CD38 is expressed on normal human erythrocytes; daratumumab in the patient's plasma binds CD38 on all reagent donor red cells used in compatibility testing, and the bound daratumumab is detected by the anti-human IgG Coombs reagent — producing a pan-reactive false-positive that masks true alloantibody detection; the blood bank must use specialized methods such as DTT (dithiothreitol)-treated reagent cells that have CD38 cleaved from their surface, or molecular blood group genotyping, to identify compatible units.
E) Daratumumab is an IgG1 antibody with strong complement-fixing activity that activates the classical pathway on all test-tube reagent red cells during the indirect antiglobulin test incubation step; the complement deposition causes non-specific agglutination unrelated to true blood group incompatibility; using low-ionic-strength saline (LISS) instead of albumin enhancement medium eliminates the complement activation and restores normal crossmatch interpretation.
ANSWER: D
Rationale:
CD38 is expressed ubiquitously on hematopoietic cells including plasma cells and plasmablasts (the therapeutic targets), but also at lower levels on normal erythrocytes, NK cells, monocytes, and some T-cell subsets. When daratumumab is present in a patient's serum — at therapeutic concentrations during active treatment — it binds CD38 on all erythrocyte surfaces encountered in the blood bank laboratory, including the reagent red cells used for antibody screening, antibody identification panels, and crossmatch testing. The anti-human IgG Coombs reagent used in indirect antiglobulin testing detects daratumumab bound to these CD38-positive reagent cells, producing a pan-reactive positive signal on every cell tested. This pan-reactivity masks the detection of true alloantibodies (such as anti-Kell, anti-Duffy, or anti-Kidd) that would indicate genuine incompatibility. In an emergency, the blood bank must use validated workaround methods: dithiothreitol (DTT) treatment of reagent red cells chemically reduces the disulfide bonds in CD38, destroying CD38 expression and eliminating daratumumab binding while preserving most blood group antigens (though Kell antigens are also destroyed by DTT, requiring molecular genotyping for Kell compatibility); alternatively, molecular blood group genotyping of the patient and donor identifies antigen-compatible units without relying on serological testing. This must be communicated to the clinical team proactively to avoid transfusion delays.
Option A: Option A is incorrect because daratumumab-induced warm autoimmune hemolytic anemia is a recognized but uncommon adverse effect and is not the mechanism of the pan-reactive crossmatch; the pan-reactivity is caused by daratumumab binding CD38 on reagent cells, not by autoantibody formation.
Option B: Option B is incorrect because daratumumab does not activate complement on the patient's own erythrocytes in this manner; the laboratory interference is due to daratumumab in plasma binding CD38 on reagent donor cells during testing.
Option C: Option C is incorrect because HLA antibody formation is not caused by daratumumab-mediated B-cell hyperactivation; HLA alloimmunization reflects prior transfusion or pregnancy history; and the clinical instruction to withhold all blood in a hemorrhaging patient regardless of emergency is not correct blood bank practice.
Option E: Option E is incorrect because daratumumab's IgG1 Fc complement-fixing activity is not the mechanism of the crossmatch interference; LISS substitution would not resolve the CD38-binding pan-reactivity.
8. A 38-year-old man with CVID (common variable immunodeficiency) was switched from monthly IVIG infusions to weekly home SCIG (subcutaneous immunoglobulin) injections eight months ago. His IgG trough levels have been consistently above 700 mg/dL and he has had no infections. He now presents with progressive ascending weakness, areflexia, and albuminocytologic dissociation on CSF analysis (cerebrospinal fluid showing elevated protein with normal cell count), consistent with GBS (Guillain-Barré syndrome). His neurologist recommends high-dose immunoglobulin treatment. Which of the following best explains why his current SCIG regimen cannot serve as the treatment for his GBS, and what change is required?
A) SCIG cannot provide the high peak IgG concentrations required for the immunomodulatory mechanisms operative in GBS — specifically FcRn saturation sufficient to accelerate pathogenic autoantibody catabolism and Fc-gamma receptor blockade at the concentrations needed for rapid effect; GBS requires 1 to 2 g/kg of IgG administered intravenously over 2 to 5 days to achieve the necessary peak levels, which the subcutaneous route's slow absorption cannot replicate.
B) SCIG uses a different IgG preparation than IVIG — subcutaneous preparations are enriched for IgG4 subclass to reduce complement activation at injection sites, making them less effective in GBS where IgG1 and IgG3 subclasses are required for anti-idiotypic neutralization of anti-ganglioside antibodies.
C) His SCIG trough IgG of 700 mg/dL is already in the immunomodulatory range; the correct approach is to double his weekly SCIG dose to 2 g/kg total delivered over four weekly injections rather than switching to IV administration, as this achieves equivalent total IgG exposure while maintaining the convenience of home therapy.
D) SCIG is contraindicated in patients with active neurological disease because subcutaneous IgG cannot cross the blood-brain barrier, and GBS treatment requires intrathecal IgG delivery to modulate the inflammatory response within the peripheral nervous system; intravenous IVIG must be replaced with intrathecal immunoglobulin infusion.
E) The problem is not the route but the IgG subclass distribution; his CVID is associated with IgG2 subclass deficiency, and his current SCIG preparation does not contain adequate IgG2; GBS is driven by IgG2 anti-ganglioside antibodies requiring anti-idiotypic neutralization by IgG2-enriched IVIG that must be obtained from a specialized fractionation supplier.
ANSWER: A
Rationale:
This question requires integrating two principles: the dose-mechanism relationship of immunoglobulin therapy and the pharmacokinetic limitation of the subcutaneous route for immunomodulatory indications. SCIG and IVIG contain the same polyspecific pooled IgG but are fundamentally different in their pharmacokinetic profiles. SCIG is absorbed slowly through subcutaneous lymphatics and capillaries, producing stable, steady-state serum IgG levels without high peaks — which is ideal for replacement therapy in CVID, where consistent trough levels prevent infections. However, the immunomodulatory mechanisms required in GBS — particularly FcRn saturation (to accelerate catabolism of pathogenic anti-ganglioside IgG antibodies) and Fc-gamma receptor blockade on macrophages and monocytes — depend on achieving very high peak serum IgG concentrations, typically 1 to 2 g/kg delivered intravenously over 2 to 5 days. The subcutaneous route cannot generate these peak concentrations regardless of total dose delivered, because the slow absorption rate prevents the acute serum concentration spike required. This patient's GBS must be treated with standard intravenous IVIG at 1 to 2 g/kg despite his already-therapeutic SCIG program — the two are not interchangeable for different indications even though both deliver the same IgG.
Option B: Option B is incorrect because SCIG and IVIG preparations are not meaningfully different in IgG subclass composition for clinical purposes; both are derived from pooled donor plasma with representative IgG subclass distributions; subclass-based distinctions between routes are not established in the clinical literature.
Option C: Option C is incorrect because delivering 2 g/kg total over four weekly subcutaneous doses does not replicate the pharmacokinetic profile of 2 g/kg IV over 2 to 5 days; the peak serum concentration achieved by IV delivery is the mechanistically relevant parameter, not total dose over time.
Option D: Option D is incorrect because GBS does not require intrathecal immunoglobulin delivery; IVIG works systemically by reducing pathogenic antibody levels and modulating peripheral macrophage function; there is no established intrathecal IVIG therapy for GBS.
Option E: Option E is incorrect because GBS anti-ganglioside antibodies are predominantly IgG1 and IgG1/IgG3 class, not IgG2; and SCIG preparations contain all IgG subclasses representative of donor plasma; subclass-specific treatment is not an established approach.
9. A 68-year-old man with relapsed multiple myeloma has developed grade 3 peripheral neuropathy (severe sensory loss limiting activities of daily living) after six cycles of bortezomib. His oncologist must select a proteasome inhibitor that maintains anti-myeloma efficacy while minimizing further neuropathy. She considers carfilzomib and ixazomib. Which of the following best integrates the mechanisms and clinical profiles of these agents to guide the selection?
A) Carfilzomib should be avoided because it is an irreversible proteasome inhibitor like bortezomib, and irreversible inhibition is the primary mechanism of bortezomib neuropathy; ixazomib is preferred because its reversible binding to the beta5 proteasome subunit spares dorsal root ganglion neurons from sustained proteasome inhibition, allowing recovery between doses and preventing cumulative neuropathy.
B) Carfilzomib is an irreversible proteasome inhibitor with greater selectivity for the beta5 (chymotrypsin-like) catalytic subunit of the 20S proteasome than bortezomib; its more selective inhibition profile results in substantially lower rates of peripheral neuropathy than bortezomib despite also being covalent; ixazomib is an oral reversible proteasome inhibitor with a lower neuropathy rate than bortezomib and the practical advantage of oral administration, but carries its own toxicity profile including gastrointestinal adverse effects and rash; carfilzomib's primary dose-limiting concern is cardiovascular toxicity rather than neuropathy.
C) Ixazomib is preferred over carfilzomib specifically in this patient because ixazomib inhibits the beta1 (caspase-like) proteasome subunit rather than the beta5 subunit, providing a mechanistically non-overlapping form of proteasome inhibition that does not aggravate bortezomib-induced beta5 inhibition neuropathy while maintaining plasma cell cytotoxicity through a separate catalytic pathway.
D) Both carfilzomib and ixazomib carry identical neuropathy rates to bortezomib because peripheral neuropathy from proteasome inhibitors is a class effect driven by proteasome blockade in all tissues, including dorsal root ganglia; the only clinically meaningful difference is route of administration — carfilzomib is intravenous and ixazomib is oral — and the choice should be based solely on patient preference and infusion center access.
E) Carfilzomib causes more severe neuropathy than bortezomib because its irreversible covalent bond with the proteasome active site provides no opportunity for dorsal root ganglion neuronal proteasome recovery between doses; ixazomib and bortezomib are equivalent in neuropathy risk because both are boron-containing reversible inhibitors that recover from proteasome binding within 24 to 48 hours.
ANSWER: B
Rationale:
This question requires integrating proteasome inhibitor mechanisms with their distinct toxicity profiles for clinical decision-making. Bortezomib, carfilzomib, and ixazomib all inhibit the 26S proteasome, primarily targeting the beta5 (chymotrypsin-like) catalytic subunit, but they differ pharmacologically in ways that produce different adverse effect profiles. Carfilzomib is an irreversible (covalent) epoxyketone-based inhibitor with greater beta5 subunit selectivity than bortezomib; despite being covalent, its more selective inhibition of beta5 versus beta1 and beta2 subunits results in substantially lower rates of peripheral neuropathy compared to bortezomib (approximately 17% vs. 30 to 40%), making it a reasonable choice for patients with bortezomib-induced neuropathy. Carfilzomib's primary dose-limiting toxicity is cardiovascular — particularly hypertension and cardiac dysfunction including cardiomyopathy and heart failure — not neuropathy. Ixazomib is an oral boron-containing reversible inhibitor with a lower neuropathy rate than bortezomib and the major practical advantage of oral administration for outpatient therapy; its principal toxicities include gastrointestinal effects (nausea, diarrhea) and skin rash. For this patient with severe existing neuropathy, either could be chosen, but understanding the distinct toxicity profile shift is the key clinical insight.
Option A: Option A is incorrect because the reversibility of proteasome binding is not the primary mechanism of bortezomib neuropathy; the neuropathy relates to off-target effects on dorsal root ganglion protein homeostasis and NF-kappaB signaling; carfilzomib's lower neuropathy rate despite being irreversible shows that irreversibility per se is not the neurotoxic factor.
Option C: Option C is incorrect because ixazomib also primarily targets the beta5 subunit of the proteasome, not the beta1 (caspase-like) subunit; the premise of mechanistically non-overlapping subunit selectivity is pharmacologically inaccurate.
Option D: Option D is incorrect because carfilzomib and ixazomib do not carry identical neuropathy rates to bortezomib; both have substantially lower neuropathy rates, and the clinical decision is meaningfully informed by these differences.
Option E: Option E is incorrect because carfilzomib has lower neuropathy rates than bortezomib despite being irreversible; ixazomib is a boron-containing inhibitor (correct) but is not equivalent to bortezomib in neuropathy risk — it has a lower rate; the claim that irreversibility determines neuropathy severity is refuted by carfilzomib's clinical profile.
10. A 45-year-old man with PNH has been on iptacopan monotherapy for 14 months with excellent hemoglobin response (hemoglobin 13.2 g/dL) and no thrombotic events. He requires elective cholecystectomy. His surgeon notes he is on "a complement inhibitor" but is uncertain whether the same infection precautions apply as with eculizumab. Which of the following best applies the pharmacology of iptacopan to perioperative infection risk assessment?
A) Iptacopan selectively inhibits the alternative pathway only and leaves the classical and lectin pathways fully intact; because MAC (membrane attack complex) formation requires terminal complement activation that depends on all three pathways converging, iptacopan does not meaningfully impair terminal complement bactericidal defense and carries no increased meningococcal infection risk perioperatively.
B) Iptacopan's perioperative infection risk is limited to encapsulated bacteria other than Neisseria meningitidis because its alternative pathway selectivity blocks amplification of C3b opsonization but preserves the classical pathway C3 convertase, maintaining IgG-dependent opsonophagocytic clearance of meningococcus through antibody-dependent complement activation.
C) Iptacopan should be discontinued two weeks before surgery to allow complement function to recover fully; Factor B, the target of iptacopan, has a plasma half-life of approximately 14 days, so normal alternative pathway activity is restored within two weeks of drug cessation, eliminating perioperative infection risk.
D) Iptacopan carries no meaningful infection risk because it does not directly block MAC formation — it inhibits alternative pathway amplification rather than the terminal complement pathway; MAC-mediated bactericidal killing of Neisseria meningitidis is therefore fully preserved in iptacopan-treated patients, and no special perioperative infection precautions beyond standard surgical prophylaxis are required.
E) Iptacopan inhibits Factor B, blocking alternative pathway C3 convertase assembly; because the alternative pathway provides approximately 80 to 90% of total complement amplification once activated, Factor B inhibition substantially impairs terminal complement generation including MAC formation despite not directly targeting C5 or the MAC components; meningococcal vaccination is required before iptacopan initiation and heightened vigilance for encapsulated bacterial infections applies perioperatively, similar to other complement inhibitors.
ANSWER: E
Rationale:
This question requires integrating the pharmacology of alternative pathway inhibition with the broader consequences for terminal complement function. The alternative pathway serves as the dominant amplification loop for complement activation — regardless of which pathway initiates complement (classical, lectin, or spontaneous tick-over), the alternative pathway amplifies C3b deposition by approximately 10-fold through the positive feedback cycle of C3b + Factor B → C3bBb (C3 convertase) → more C3b. Factor B inhibition by iptacopan disrupts this amplification loop, substantially reducing total C3b generation and thereby impairing downstream C5 convertase formation, C5 cleavage, and MAC assembly — even though iptacopan does not directly target C5 or any MAC component. The result is meaningful impairment of terminal complement bactericidal activity despite the mechanistic selectivity for the alternative pathway. This is why meningococcal vaccination is required before iptacopan initiation (as it is for all approved complement inhibitors in PNH), and why the same vigilance for fulminant meningococcal disease applies as with anti-C5 agents. Perioperatively, surgical stress and potential bacteremia amplify this risk further.
Option A: Option A is incorrect because MAC formation does not require all three pathways simultaneously — once C5 convertase is assembled through any pathway, MAC forms from C5b nucleation; alternative pathway amplification provides the majority of C3b and C5 convertase that drives MAC assembly; blocking it substantially reduces MAC formation.
Option B: Option B is incorrect because iptacopan's alternative pathway inhibition impairs amplification of C3b generation from all activating pathways, not just the alternative pathway itself; classical pathway-initiated C3b deposition is substantially amplified by the alternative pathway feedback loop, which iptacopan blocks; meningococcal risk is not confined to other encapsulated organisms.
Option C: Option C is incorrect because iptacopan inhibits Factor B (not Factor D), and Factor B's plasma half-life does not determine the recovery time of alternative pathway function after drug discontinuation; iptacopan's own half-life as a small molecule determines recovery time, which is not 14 days; elective discontinuation before surgery is not the established management strategy.
Option D: Option D is incorrect because inhibiting alternative pathway amplification does substantially impair MAC-mediated terminal complement killing despite not targeting MAC components directly; the premise that alternative pathway-specific inhibition preserves MAC formation completely misrepresents the quantitative contribution of alternative pathway amplification to total complement output.
11. A 34-year-old woman with SLE (systemic lupus erythematosus) has persistently active skin and joint disease with high anti-dsDNA antibody titers and low complement C3/C4 levels despite hydroxychloroquine, mycophenolate, and low-dose prednisone. Her rheumatologist orders a peripheral blood interferon gene signature (ISG) score, which returns as low (negative). The physician considers anifrolumab versus belimumab. Which of the following best applies the precision immunopharmacology framework to select between these agents?
A) The low ISG score confirms that type I interferons are not driving this patient's SLE and excludes anifrolumab; belimumab should also be avoided because BAFF (B-cell activating factor) signaling is downstream of type I interferon activation — in ISG-negative patients, BAFF levels are low and B-cell hyperactivation is not the disease driver; the appropriate escalation is to add cyclophosphamide.
B) The low ISG score is a contraindication to anifrolumab because administering an IFNAR1 blocker in an ISG-negative patient paradoxically upregulates type I interferon production through a negative feedback mechanism, worsening SLE activity and potentially triggering a lupus nephritis flare; belimumab is also contraindicated because anti-BAFF therapy requires an active interferon signature to be effective.
C) The low ISG score indicates that type I interferon pathway activation is not the dominant immunopathological driver in this patient, making anifrolumab an unlikely effective choice; belimumab — which targets BAFF and reduces B-cell survival and autoantibody-producing plasmablast generation through an interferon-independent pathway — is a rational alternative, as B-cell hyperactivation and anti-dsDNA antibody production may be the predominant driver of her disease activity.
D) The ISG score does not inform biologic selection in SLE because type I interferon pathway activation is constitutive in all SLE patients regardless of ISG score; both anifrolumab and belimumab work through interferon-dependent mechanisms and should be selected based on organ involvement pattern rather than biomarker profile.
E) A low ISG score in the context of high anti-dsDNA and low complement indicates complement-mediated immune complex disease rather than interferon-driven SLE; the appropriate biologic is eculizumab, which blocks terminal complement and prevents immune complex-mediated tissue injury in ISG-negative lupus nephritis.
ANSWER: C
Rationale:
This question integrates precision immunopharmacology biomarker principles with the selection between two approved SLE biologics. The ISG (interferon gene signature) score reflects the level of type I interferon pathway activation in peripheral blood cells; approximately 60 to 80% of SLE patients have a positive (high) ISG score, indicating that type I interferons are actively driving their disease — and this subset demonstrates significantly greater clinical response to anifrolumab (anti-IFNAR1). This patient's low ISG score places her in the 20 to 40% of SLE patients where type I interferon pathway activation is not the dominant immunopathological mechanism; anifrolumab is mechanistically mismatched to her disease biology. Belimumab targets BAFF (B-cell activating factor, also called BLyS), a cytokine required for B-cell survival, maturation, and differentiation into antibody-secreting cells; BAFF blockade reduces circulating B cells and plasmablasts, thereby reducing autoantibody production including anti-dsDNA. BAFF-driven B-cell hyperactivation is an interferon-independent disease pathway that is particularly relevant in patients with prominent B-cell-mediated pathology — exactly the profile suggested by her high anti-dsDNA titers and complement consumption.
Option A: Option A is incorrect because BAFF levels and B-cell hyperactivation are not downstream of type I interferon activation in a manner that renders belimumab ineffective in ISG-negative patients; BAFF signaling is a parallel B-cell survival pathway independent of the interferon axis, and belimumab has demonstrated clinical efficacy regardless of ISG status.
Option B: Option B is incorrect because anifrolumab does not paradoxically increase interferon production in ISG-negative patients through a negative feedback mechanism; this is a fabricated pharmacological construct; and belimumab is not dependent on an active interferon signature for efficacy.
Option D: Option D is incorrect because type I interferon pathway activation is not constitutive in all SLE patients; the ISG score varies substantially between patients and is a validated predictive biomarker for anifrolumab response — the premise of this option contradicts established precision medicine evidence.
Option E: Option E is incorrect because eculizumab is not approved for SLE and is not a standard of care for immune complex lupus nephritis; lupus nephritis management uses mycophenolate, cyclophosphamide, belimumab, or voclosporin, not complement terminal inhibitors.
12. A 51-year-old woman with severe pemphigus vulgaris — a life-threatening autoimmune blistering disease caused by anti-desmoglein 3 IgG antibodies — achieves initial skin remission after two courses of rituximab but relapses at six months with high anti-desmoglein 3 titers despite confirmed B-cell depletion (CD19+ B cells <1% on flow cytometry). Her dermatologist explains that a specific cell population has evaded rituximab and is driving the persistent autoantibody production. Which of the following correctly identifies this population and names two mechanistically distinct agents that target it?
A) Plasmablasts — short-lived circulating antibody-secreting cells generated during the acute disease flare — have evaded rituximab because they express an alternative form of CD20 (CD20-short isoform) not recognized by the standard rituximab epitope; obinutuzumab, which binds a different CD20 epitope, and ofatumumab, which binds the small extracellular loop, would both deplete this CD20-short-expressing population.
B) Follicular helper T cells (Tfh) — which drive germinal center reactions and provide cognate help to autoreactive B cells — have evaded rituximab because they do not express CD20; abatacept (blocks CD28 co-stimulation) and ixekizumab (anti-IL-17A) target Tfh cells through complementary mechanisms and together would prevent re-generation of anti-desmoglein plasma cells from germinal centers.
C) Bone marrow stromal cells — which provide the survival niche for long-lived plasma cells through APRIL and BAFF signaling — have evaded rituximab because they are non-hematopoietic; belimumab (anti-BAFF) and atacicept (anti-APRIL/BAFF dual blocker) would disrupt the survival niche without requiring direct plasma cell depletion.
D) Long-lived plasma cells — terminally differentiated antibody-secreting cells that have lost CD20 expression and reside in bone marrow survival niches — have evaded rituximab because they are CD20-negative; daratumumab (anti-CD38 monoclonal antibody) depletes them through ADCC, CDC, and direct apoptosis, while bortezomib (proteasome inhibitor) exploits their vulnerability to UPR (unfolded protein response) overload from high immunoglobulin synthesis rates.
E) Memory B cells — which retain CD20 expression but are rendered resistant to rituximab-mediated lysis by upregulation of complement regulatory proteins CD55 and CD59 on their surface — have evaded rituximab by blocking CDC; ofatumumab, which activates complement more potently than rituximab, and obinutuzumab, which mediates ADCC independent of complement, together would overcome this resistance mechanism.
ANSWER: D
Rationale:
This question integrates the fundamental limitation of rituximab with the pharmacological rationale for two mechanistically distinct plasma cell-directed therapies. Pemphigus vulgaris is driven by IgG autoantibodies against desmoglein 3 (and sometimes desmoglein 1), produced by antibody-secreting cells in the plasma cell lineage. The characteristic pattern of initial rituximab response followed by relapse despite confirmed B-cell depletion — with persistently elevated autoantibody titers — is the clinical fingerprint of long-lived plasma cells maintaining antibody production. Long-lived plasma cells are terminally differentiated, non-dividing cells that have completed germinal center reactions, undergone somatic hypermutation and affinity maturation, and migrated to bone marrow niches where they receive survival signals from stromal cells through APRIL, BAFF, IL-6, and CXCL12 interactions. They have irreversibly lost CD20 expression upon terminal differentiation and are pharmacologically invisible to rituximab. Two distinct approaches target them: daratumumab exploits their high CD38 expression, deploying ADCC (NK cells and macrophages), CDC (complement activation), ADCP (antibody-dependent cellular phagocytosis), and direct apoptosis induction to eliminate CD38-high plasma cells; bortezomib exploits the metabolic vulnerability created by the plasma cell's exceptional immunoglobulin synthesis rate — proteasome blockade causes misfolded protein accumulation, UPR activation, and terminal apoptosis in cells with high secretory demand.
Option A: Option A is incorrect because CD20-short isoform variants are not the established mechanism of rituximab resistance in autoimmune disease plasma cells; long-lived plasma cells do not express any CD20 isoform, and obinutuzumab and ofatumumab both require CD20 expression to work.
Option B: Option B is incorrect because Tfh cells do not drive persistent anti-desmoglein production in the absence of B cells — they require germinal center B cells; moreover, ixekizumab targets IL-17A, which is not the dominant Tfh cytokine pathway; abatacept could reduce new plasma cell generation but would not eliminate the existing plasma cell pool.
Option C: Option C is incorrect because bone marrow stromal cells are not the target population producing anti-desmoglein antibodies; belimumab and atacicept disrupt plasma cell survival signals but have shown modest effects on established long-lived plasma cells compared to direct depletion strategies; the question identifies the effector population, not the niche.
Option E: Option E is incorrect because rituximab resistance in pemphigus is not caused by CD55/CD59 upregulation on memory B cells; long-lived plasma cells lacking CD20 — not CD55/CD59-protected memory B cells — are the established mechanism; moreover, both obinutuzumab and ofatumumab still require some CD20 expression and would not address CD20-negative plasma cells.
13. An infectious disease consultant is asked to assess the meningococcal infection risk in two immunosuppressed patients on a rheumatology ward: Patient 1 has PNH and is on eculizumab; Patient 2 has GPA (granulomatosis with polyangiitis) and is on avacopan. Both patients received meningococcal vaccination before starting their respective therapies. The consultant is asked whether the same level of meningococcal vigilance applies to both patients. Which of the following best applies the pharmacological mechanisms of these two agents to compare their relative impact on meningococcal defense?
A) Patient 1 (eculizumab) carries substantially higher meningococcal risk than Patient 2 (avacopan); eculizumab prevents C5 cleavage and completely abolishes MAC formation — the primary bactericidal mechanism against Neisseria meningitidis — while avacopan blocks only C5aR1 on neutrophils and allows C5 cleavage to proceed, preserving C5b generation and MAC assembly; both patients warrant vigilance, but Patient 1's risk is greater because bactericidal terminal complement is pharmacologically eliminated, whereas Patient 2 retains MAC-mediated killing.
B) Both patients have identical meningococcal risk because both drugs ultimately block C5a-mediated neutrophil activation — eculizumab by preventing C5a generation and avacopan by blocking its receptor — and neutrophil-mediated phagocytosis of Neisseria is the dominant host defense mechanism; MAC formation plays no independent role in meningococcal clearance.
C) Patient 2 (avacopan) carries higher meningococcal risk than Patient 1 (eculizumab) because avacopan allows unblocked C5 cleavage and unrestricted C5a generation, which continuously activates macrophages and NK cells through C5aR2 to promote an inflammatory state that paradoxically impairs directed bactericidal killing; eculizumab's complete C5 blockade preserves a balanced innate immune state more conducive to pathogen clearance.
D) Neither patient has elevated meningococcal risk if they are vaccinated, because antibody-mediated opsonophagocytosis and FcgammaR-mediated neutrophil killing are the dominant mechanisms against Neisseria in vaccinated individuals; MAC-mediated lysis is relevant only in unvaccinated complement-deficient patients; vaccination eliminates the complement-dependence of meningococcal clearance.
E) Both patients have equal and minimal meningococcal risk because both drugs are administered with mandatory prophylactic antibiotics; antibiotic prophylaxis completely eliminates meningococcal colonization and transmission and renders the pharmacological mechanism of complement inhibition irrelevant to infection risk once prophylaxis is established.
ANSWER: A
Rationale:
This question requires integrating the distinct mechanisms of eculizumab and avacopan to predict their differential impact on the specific host defense mechanism most relevant to meningococcal disease. Neisseria meningitidis is uniquely vulnerable to complement-mediated killing — specifically MAC (membrane attack complex) formation — because its outer membrane is thin and susceptible to complement-mediated lysis; humans with genetic terminal complement deficiencies (C5–C9) have dramatically elevated susceptibility to recurrent meningococcal disease, establishing MAC as the dominant bactericidal mechanism against this organism. Eculizumab prevents C5 cleavage, blocking all C5b generation and completely abolishing MAC formation — the pharmacological equivalent of inherited terminal complement deficiency. Avacopan acts downstream of C5 cleavage at the C5a receptor: C5 is still cleaved by the C5 convertase, generating both C5a (blocked at C5aR1 by avacopan) and C5b; C5b remains available to nucleate MAC assembly via sequential C6, C7, C8, and C9 recruitment, and MAC formation on Neisseria membranes is preserved. Therefore, Patient 2 retains terminal complement bactericidal defense while Patient 1 does not; both warrant meningococcal vigilance (vaccination is mandatory for both, and breakthrough cases have occurred in vaccinated patients on both agent classes), but the absolute risk is substantially greater for Patient 1.
Option B: Option B is incorrect because MAC-mediated bactericidal killing of Neisseria is not redundant with neutrophil phagocytosis — individuals with isolated terminal complement deficiencies (no neutrophil deficit) have dramatically elevated meningococcal susceptibility, proving MAC is an independent and essential defense mechanism.
Option C: Option C is incorrect because C5a generation in avacopan-treated patients does not paradoxically impair meningococcal killing; the C5aR2 pathway (partially anti-inflammatory) does not override bactericidal MAC function; eculizumab's complete MAC blockade carries higher, not lower, meningococcal risk than avacopan.
Option D: Option D is incorrect because anti-meningococcal vaccination provides bactericidal antibodies but does not restore complement function; vaccinated patients with complement deficiency still have substantially elevated meningococcal risk compared to vaccinated complement-intact individuals; vaccination attenuates but does not eliminate complement-dependence of meningococcal clearance.
Option E: Option E is incorrect because prophylactic antibiotics reduce colonization risk but do not eliminate it; breakthrough meningococcal disease has occurred in vaccinated, antibiotic-prophylaxed patients on eculizumab; antibiotic prophylaxis is risk-reduction, not risk-elimination.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.